Unicycive Stock Rockets 153% After Securing $130M Financing to Commercialize Renazorb

Seeking Alpha2023-03-07

Shares of kidney disease company, Unicycive Therapeutics (NASDAQ:UNCY) jump 153% on Monday after the Company signed a securities purchase agreement with certain institutional investors that will ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

Steven16
2023-03-09
Steven16
新药啥时估计能批准上市？

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2317912071?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2023-03-07 10:25","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2317912071","market":"us","top_or_hot":-1,"title":"Unicycive Stock Rockets 153% After Securing $130M Financing to Commercialize Renazorb","media":"Seeking Alpha","content":"<div>\n<p>Shares of kidney disease company, Unicycive Therapeutics (NASDAQ:UNCY) jump 153% on Monday after the Company signed a securities purchase agreement with certain institutional investors that will ...</p>\n\n<a href=\"https://seekingalpha.com/news/3944370-unicycive-stock-rockets-114-after-securing-130m-financing-to-commercialize-renazorb\">网页链接</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Unicycive Stock Rockets 153% After Securing $130M Financing to Commercialize Renazorb</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUnicycive Stock Rockets 153% After Securing $130M Financing to Commercialize Renazorb\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-03-07 10:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3944370-unicycive-stock-rockets-114-after-securing-130m-financing-to-commercialize-renazorb><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of kidney disease company, Unicycive Therapeutics (NASDAQ:UNCY) jump 153% on Monday after the Company signed a securities purchase agreement with certain institutional investors that will ...</p>\n\n<a href=\"https://seekingalpha.com/news/3944370-unicycive-stock-rockets-114-after-securing-130m-financing-to-commercialize-renazorb\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://seekingalpha.com/news/3944370-unicycive-stock-rockets-114-after-securing-130m-financing-to-commercialize-renazorb","article_id":"2317912071","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2317912071","pubTimestamp":1678155949,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Shares of kidney disease company, Unicycive Therapeutics (NASDAQ:UNCY) jump 153% on Monday after the","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","UNCY":"Unicycive Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Unicycive股票在获得1.3亿美元融资将Renazorb商业化后飙升153%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UNCY":1},"content_text":"Shares of kidney disease company, Unicycive Therapeutics (NASDAQ:UNCY) jump 153% on Monday after the Company signed a securities purchase agreement with certain institutional investors that will provide up to $130M in gross proceeds to Unicycive through a private placement, including initial upfront funding of $30M.The company remains on track to file a New Drug Application (NDA) for Renazorb marketing approval with the FDA in mid-year.Proceeds from the offering will be used to support the Company’s NDA submission of Renazorb for the treatment of hyperphosphatemia in the U.S. and, if approved, for the commercial launch of Renazorb in the U.S.The funding is being led by Vivo Capital with participation from RA Capital, BVF Partners, Logos Capital, and is supported by existing investors Nantahala Capital Partners and Rosalind Advisors. Gaurav Aggarwal, M.D., Managing Director of Vivo Capital, will join the Unicycive Board of Directors.Pursuant to the securities purchase agreement, the Company will issue to purchasers (i) $30M in shares of Series A Convertible Preferred Stock and (ii) three tranches of warrants exercisable for convertible preferred stock.Shares of Series A Convertible Preferred Stock will be issued at a price of $1,000.00 per share.In December 2022, Unicycive announced that the primary endpoint was met in its bioequivalence study comparing Renazorb to Fosrenol.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":627248985,"gmtCreate":1678375143747,"gmtModify":1678375145413,"author":{"id":"3433494838648625","authorId":"3433494838648625","name":"Steven16","avatar":"https://static.tigerbbs.com/60af47707be9d6bacdbeb4efb27ae9f5","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"新药啥时估计能批准上市？","listText":"新药啥时估计能批准上市？","text":"新药啥时估计能批准上市？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/627248985","repostId":2317912071,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2317912071"}